Showing results (121-130 of 168) with videos related to
Sort By:
Pageof 17
BMC Medical Genetics|August 5, 2011
Genome-wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish populationXinmin Liu, Rong Cheng, Miguel Verbitsky, et al.NPJ Parkinson'S Disease|September 5, 2020
COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedsideDavid Sulzer, Angelo Antonini, Valentina Leta, et al.Journal of Parkinson'S Disease|January 23, 2026
Analysis of α-synuclein seed amplification assay in carriers of GBA1 and LRRK2 pathogenic variantsKyle B Fraser, Anat Mirelman, Omar S Mabrouk, et al.Movement Disorders : Official Journal of the Movement Disorder Society|July 30, 2010
Cancer incidence in a trial of an antiapoptotic agent for Parkinson's diseaseSteven R Schwid, Janice Bausch, David Oakes, et al.Archives of Neurology|May 13, 2009
Association of glucocerebrosidase mutations with dementia with lewy bodiesLorraine N Clark, Lykourgos A Kartsaklis, Rebecca Wolf Gilbert, et al.Movement Disorders : Official Journal of the Movement Disorder Society|February 12, 2014
A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND studyCaroline M Tanner, Cheryl C Meng, Bernard Ravina, et al.Archives of Neurology|April 17, 2008
Serum urate as a predictor of clinical and radiographic progression in Parkinson diseaseMichael A Schwarzschild, Steven R Schwid, Kenneth Marek, et al.Brain : a Journal of Neurology|December 22, 2020
Targeted sequencing of Parkinson's disease loci genes highlights SYT11, FGF20 and other associationsUladzislau Rudakou, Eric Yu, Lynne Krohn, et al.Neurobiology of Aging|March 30, 2021
LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's diseaseYuri L Sosero, Eric Yu, Lynne Krohn, et al.Drug Safety|May 9, 2003
Benefits and risks of pharmacological treatments for essential tremorKelly E Lyons, Rajesh Pahwa, Cynthia L Comella, et al.Pageof 17